Skip to main content

Table 4 AIT-like desensitization protocol for laronidase

From: Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)

step

inj # 1

inj # 2

inj # 3

inj # 4

*total

(U)

 

conc. (U/ml)

vol.

(ml)

U

conc.

(U/ml)

vol.

(ml)

U

conc.

(U/ml)

vol.

(ml)

U

conc.

(U/ml)

vol.

(ml)

U

 

1

10

0.01

1

10

0.02

2

10

0.03

3

10

0.03

3

9

2

10

0.03

3

10

0.06

6

10

0.06

6

10

0.06

6

21

3

100

0.1

10

100

0.1

10

100

0.15

15

100

0.15

15

50

4

100

0.15

15

100

0.15

15

100

0.3

30

100

0.6

60

120

5

100

1

100

100

1

100

100

1

100

100

1

100

400

6

100

1

100

100

1

100

500

0.4

200

500

0.4

200

600

7

500

0.4

200

500

0.4

200

500

0.6

300

500

1

500

1,200

8

500

1

500

500

1

500

500

1

500

500

1

500

2,000

9

500

1

500

500

1

500

500

1

500

500

1

500

2,000

10

500

1

500

500

1

500

500

1

500

500

1

500

2,000

11

500

1

500

500

1

500

500

1

500

500

1

500

2,000

  1. Total dose administered over approx. 24 days: 10,400 U (60.32 mg). Inj #1 – Inj #4: at each step/session 3 or 4 subcutaneous injections were given, 20’ apart from each other. *Total dose administered at each step (consisting of 3-4 subcutaneous injections). At steps 1 and 2, laronidase was used diluted 10-fold in saline. From step 6 (injections #3 and #4, only) to step 11, laronidase was used concentrated 5-fold by ultrafiltration (see below)